At this point, tirzepatide seems to be the GIP/GLP-1 receptor co-agonist closest to having enough evidence for a potential recommendation in MASLD and even MASH-related fibrosis. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.